$4523.T-JP News
Last published 2y ago
- 2y agoESALY4523.T-JPBIIBAlzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatmentCNBCLeqembi's rollout has been slowed by bottlenecks related to reimbursement uncertainties, diagnostic test requirements and regular brain scans, among others.
- 2y ago4523.T-JPBIIBPatients on Alzheimer's drug Leqembi see benefits over three years, Eisai study saysCNBCThe study results on Leqembi, which Eisai shares with Biogen, also found that Alzheimer's patients who take the therapy get worse after they stop treatment.
- 2y ago4523.T-JPBIIBLLYEuropean drug regulator rejects Alzheimer's treatment Leqembi from Biogen, EisaiCNBCThe committee said Leqembi's effect on delaying cognitive decline does not outweigh "the risk of serious side effects associated with the medicine."
- 2y agoBIIB4523.T-JPBiogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatmentsCNBCBiogen said its decision to drop Aduhelm, which had a polarizing approval and launch, was "not related to any safety or efficacy concerns."
- 2y agoLLYNOVO.B-DKPFEAMGN+6Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharmaCNBCWall Street turned its focus to a handful of newer treatments in different disease areas in 2023, including weight loss medications and a new Alzheimer's drug.
- 3y ago4523.T-JPBIIBMore convenient form of breakthrough Alzheimer's drug Leqembi shows promising results in studyCNBCEisai and Biogen said in a release that they plan to apply for U.S. approval of subcutaneous Leqembi by the end of March.
- 3y agoBIIB4523.T-JPMedicare will pay for Alzheimer's drug Leqembi. What patients and doctors should knowCNBCPatients with early Alzheimer's disease could still pay more than $5,000 in out-of-pocket costs for Leqembi even with Medicare coverage.
- 3y ago4523.T-JPBIIBSales of Alzheimer’s drug Leqembi may be slow initially but could pick up in 2024CNBCAnalysts believe the Medicare registry requirement and new guidance on Leqembi's prescription label could potentially weigh on sales in the near term.
- 3y agoMETADKNGFSLRBABA+5Stocks making the biggest moves midday: Rivian, Levi Strauss, Biogen, First Solar and moreCNBCThese are the stocks posting the largest moves in midday trading.
- 3y ago4523.T-JPBIIBFDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverageCNBCLeqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.
- 3y ago4523.T-JPBIIBLLYAlzheimer's treatment Leqembi could cost Medicare up to $5 billion per year, study estimatesCNBCThe authors said the estimated cost of Leqembi to Medicare are conservative, and spending on the Alzheimer's treatment may increase more than anticipated.
- 3y agoDGXLLYBIIB4523.T-JP+3Alzheimer’s patients may wait years to get treated with new drugs, putting them at risk of more severe diseaseCNBCPatients could face wait times ranging from 18 months to four years or more to get diagnosed and then treated for Alzheimer's disease.
- 3y agoBIIB4523.T-JPLLYAlzheimer’s patients retain the benefits of Leqembi even when they stop the drug, Eisai saysCNBCAlzheimer's patients who take Leqembi retain the benefits of the treatment even when they stop taking it, new research by Eisai and Biogen shows.
- 3y agoBIIB4523.T-JPLLYAlzheimer’s patients retain the benefits of Leqembi even when they stop the drug, Eisai saysCNBCAlzheimer's patients who take Leqembi retain the benefits of the treatment even when they stop taking it, new research by Eisai and Biogen shows.
- 3y agoBIIB4523.T-JPFDA approves Alzheimer's drug that slowed cognitive decline in clinical trialCNBCThe FDA's decision comes after clinical trial results indicated that lecanemab slows cognitive decline somewhat in people with mild impairment from Alzheimer's.
- 4y ago4523.T-JPBIIBWhy Biogen's Alzheimer's drug Aduhelm is so controversialCNBCBiogen's Alzheimer's drug Aduhelm was heralded as a historic triumph against the memory-robbing disease. Now, the company is trying to keep it afloat.